Platform

Cell Expansion

Cell Expansion

Tacitus Therapeutics’ cell expansion platform uses a simple and efficient method to improve the quantity and quality of engraftable hematopoietic stem cells (HSCs) for use in transplantation. Tacitus Therapeutics’ technology aims to overcome significant challenges with the current standard of care for HSC transplants by reducing the risk of life-threatening graft vs. host disease (GVHD) and graft rejection. HSC100 is currently in clinical trials.1

1ClinicalTrials.gov identifier NCT03885947.

Cell Differentation

Cell Differentiation

Tacitus Therapeutics’ stem cell differentiation technology uses a simple and efficient method to generate megakaryocytes from HSCs. Megakaryocytes are platelet producing cells with potential to alleviate the need for repeated donor platelet transfusions in patients with conditions associated with low platelet counts such as thrombocytopenia. Tacitus Therapeutics aims to cure this condition by infusing megakaryocytes into patients, which then provide a constant, natural supply of platelets in the body. Tacitus Therapeutics’ MEG100 therapy is in preclinical phase.

Patel A, Clementelli CM, Jarocha D, Mosoyan G, Else C, Kintali M, Fong H, Tong J, Gordon R, Gillespie V, Keyzner A, Poncz M, Hoffman R, Iancu-Rubin C. Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice. Transfusion. 2019 Dec.

Cell Engineering

Tacitus Therapeutics’ proprietary cell engineering technologies enable modification of expanded HSCs and cells derived from them. We are exploring the use of gene modification technologies for a future pipeline of functionalized cell therapies for immune and genetic disorders, and actively seeking partners in this area.